Track 1: Diabetes Mellitus
Diabetes is a common chronic illness that puts a lot of stress on a person's immune system. Type 1diabetes, type 2 diabetes, and gestational diabetes are the three subtypes of the disease. The auto-immune destruction of the insulin-producing beta cells of the pancreas results in Type 1 Diabetes Mellitus. Type 1 diabetes and type 2diabetes can be distinguished using auto-antibody testing and the C-peptide test. 10% of people with diabetes have diabetes type 1. A metabolic disorder called diabetes mellitus type 2 is characterised by insulin resistance and a shortage of insulin.
1. Type 1 Diabetes Mellitus
2. Type 2 Diabetes Mellitus
Track 2: Types of Diabetes and Complications
Acute hyperglycemia and other conditions that might be fatal, like severe consequences that harm the body's organ systems, are examples of diabetes complications. Due to the lack of international consensus on standard diabetes diagnosis, it is difficult to estimate the prevalence of diabetic complications. At this session of the Diabetes Congress 2023, issues relating to cardiovascular systems, retinopathy, and nephropathy will be covered.
1. Skin Conditions
2. Pre-diabetes
3. Dental Health
4. Nephropathy
5. Eye Damage (Retinopathy)
6. Neuropathy
7. Cardiovascular problems
Track 3: Gestational Diabetes
GDM (Gestational Diabetes Mellitus) is a growing global health problem that can have both immediate and long-term negative effects on the mother and the child. Despite how important it is, many countries still lack the epidemiological information required to address diabetes-related disorders. Due to a lack of knowledge about GDM, diabetes and obesity are common in many nations. According to research, one in three women of childbearing age and one in every seven children have diabetes. This session will address a range of issues related Gestational Diabetes.
1. Overview: Diabetes and Women's Health
2. Diabetes symptoms in women
3. Diabetes-Free Pregnancy- Strategy
4. Postpartum Recommendations.
Track 4: Genetic Diabetes
Many people still don't understand what hereditary diabetes is on a global scale. This makes it possible for people to go through pre- diabetic stages without ever realising it, which results in a wide range of issues. Some persons are predisposed to developing diabetic problems as a result of inherited elements that are triggered. From birth, we are predisposed to diabetes, and our environment serves as the trigger. But this isn't always the case. The diabetic circumstances may be thresholded by other events. The therapies and measures that must be done to prevent inherited Diabetes will be covered in this genetic Diabetes presentation.
1. Predictions and safeguards
2. Factors triggering genetic diabetes
3. Genes and Family History
4. Genetic Diabetes Complications
Track 5: Diagnosis, Management and Prevention of Diabetes
High blood sugar levels are a defining feature of diabetes mellitus, also referred to as diabetes. Insulin is a hormone that moves blood sugar into your cells, where it can be stored or used as fuel. If you have diabetes, your body either produces insufficient insulin or uses the insulin it does make inefficiently. Blood sugar levels rising worsen diabetes symptoms. When people with typical diabetes symptoms visit, the great majority are given a precise diagnosis. Diabetes management attempts to promote the quality of life and productivity of diabetics.
1. Diabetes education includes both type 1 and type 2 diabetes.
2. Diabetes during pregnancy
3. Diabetes risk factors and symptoms
4. Blood sugar levels at random and during fasting
5. Diet and physical exercise in diabetes
6. Diabetes medication management
Track 6: Artificial Intelligence: The Future for Diabetes Care?
A discipline of computer science that attempts to build systems or methods for processing information and managing complexity in a wide range of applications" is how artificial intelligence (AI) is defined. AI is a sensible and alluring option for efficient data management and the development of tools and gadgets for the treatment of diabetes. The field of artificial intelligence (AI), which is rapidly expanding, has the potential to change how diabetes is detected and managed. Diabetes is a global pandemic. The development of algorithms to enable predictive models for the risk of diabetes and its complications has made use of machine learning techniques.
1. Artificial Intelligence in Diabetes Education
2. AI and big data in diabetes control
3. AI Diagnosis of Diabetic Retinopathy
4. Monitoring for Complications
Track 7: Diabetes Physiology and Pathophysiology
The study of an organism's internal systems and processes is known as physiology. Disease physiology frequently involves complex interactions between several organs and tissue types. Both the body's supply of and ability to utilise insulin play a role in the pathophysiology of diabetes. Insulin is absent in type 1 diabetes, whereas peripheral tissues in type 2 diabetes are resistant to the effects of insulin. The aetiology of diabetes is complex and involves numerous hormones (i.e., insulin, glucagon, and growth). Because of how these hormones interact with the liver and how they affect renal function, it is difficult to pinpoint the pathological processes underlying this illness and they differ greatly among patients.
1. Diabetes management
2. Diabetes and Chronic Oxidative Stress
Track 8: Insulin Devices and Diabetes Medication
The main cause of diabetes is the body's inability to produce insulin. Depending on how long it takes for an impact to manifest, insulin is categorised into various classes. For diabetics who are unable to manage their condition with oral treatments, insulin is injected. Modern technology and diabetes medicine are mostly emphasised.
1. Rapid-acting insulin
2. Short-acting insulin
3. Intermediate-acting insulin
4. Long-acting insulin
Track 9: Cardio-Diabetes
Inflammation is a hallmark of the metabolic and cardiovascular condition known as diabetes. Nearly every cardiovascular risk factor is increased, and heart disease is the leading cause of death among diabetes. New opportunities for enhancing cardiovascular outcomes in diabetic patients have been opened up by recent advances in clinical research and patient education. The pathogenesis of diabetes and cardiovascular disease (CVD) is complicated. Clinicians can identify and treat CVD in diabetic patients with the help of an understanding of these complex disease processes, and patients can prevent potentially fatal consequences.
Cardiovascular conditions that affect diabetics and are not brought on by another recognised CVD, such as hypertension or coronary artery disease, are referred to as diabetic cardiomyopathy. Due to morphological and functional defects in diabetic cardiomyopathy, diabetes patients are predisposed to heart failure even early in the course of their disease.
1. Diabetes and Cardiovascular Interaction
2. Diabetes and Cardiovascular Disease
3. Diabetes-Related Cardiomyopathy
Track 10: Diabetes and Obesity
Obesity frequently results from an underlying disorder marked by an excessive buildup of body fat. It seriously harms one's health, notably by increasing the risk of other chronic conditions including diabetes and heart disease. A BMI of more than 30 kg/m2 is considered obese. In affluent countries, obesity is one of the most common problems, and it is becoming more common.
Type 2 diabetes, commonly referred to as insulin-resistant diabetes or adult-onset diabetes, is more likely to develop in people who are obese. This occurs when your blood sugar level stays high for an extended amount of time. According to a study, type 2 diabetes can strike obese persons up to 80 times more frequently than it does non-obese people.
1. Metabolic Syndrome
2. Weight Loss Surgery
3. Weight control
4. Obesity, Nutrition, and Exercise
Track 11: Modern Diabetes Technologies and Treatments
The term "diabetes technology" describes the tools, resources, and software that diabetics use to better manage their blood sugar levels, prevent complications from occurring, lessen the burden of having diabetes, and improve their quality of life. Insulin delivery via a syringe, pen, or pump and blood glucose monitoring via a metre or continuous glucose monitor are the two main categories of diabetes technology. Recent developments in diabetes technology include software that serves as a medical device and supports diabetic self-management, as well as hybrid devices that test glucose and dispense insulin, some of which are automated. When used effectively, diabetic technology may enhance people's lives and health; nonetheless, the environment's complexity and quick growth may present a hurdle to patient and provider adoption.
Track 12: Endocrinology
Living things rely on hormones produced by the endocrine glands to maintain a steady blood glucose level throughout their existence, despite the fact that their consumption of glucose varies greatly. By returning the blood glucose levels to normal, hormone production in the blood stimulates the pathways. Numerous studies on the endocrine system are being conducted because it is such a crucial part of our bodies. Understanding the endocrine system better can help us develop fresh approaches to preventing diseases like diabetes.
1. Hormones and endocrine glands
2. Endocrine gland hyposecretion (leading to hormone deficiency)
3. Endocrine gland hypersecretion (leading to hormone excess)
Track 13: Paediatric Endocrinology
The study of children's endocrinology is known as paediatric endocrinology. Children with type 1 and type 2 growth problems, pubertal abnormalities, obesity, sex development variations, changes in bone and mineral composition, hypoglycemia, and different disorders of the pituitary, adrenal, parathyroid, and thyroid glands are treated by paediatric endocrinologists.
1. Immunological influences on behaviour
2. Thyroid gland enlargement
3. Endocrine activity in early-experience
4. Hormone of growth
Track 14: Metabolic Syndrome
A collection of disorders that increases the risk of diabetes, heart disease, and stroke.The metabolic syndrome is characterised by high blood pressure, high blood sugar, excessive body fat around the waist, and abnormal cholesterol levels. The illness increases a person's risk of experiencing a heart attack or stroke.
Other than a large waist circumference, the majority of diseases associated with the metabolic syndrome show no symptoms. Exercise, a healthy diet, losing weight, and quitting smoking can all be beneficial. Additionally, medication may be recommended.
1. Coronary Heart Disease
2. Diabetes
3. Stroke
Track 15: Endocrine Bone Disease
Fracture risk is raised and poor bone quality is linked to diabetes, especially type 1 diabetes. The most vulnerable individuals to fractures are those who use insulin, have uncontrolled blood sugar levels, and have chronic illnesses.
Bone metabolism and bone quality may suffer as a result of diabetes mellitus. Diabetes causes osteopenia and osteoporosis by increasing osteoclast activity while lowering osteoblast activity.
1. Redness and swelling in the affected area
2. Disorders of the Osteoporosis and Osteopenia
3. Osteoporosis in Women
4. Socio and economic impact of Osteopenia
Track 16: Neuroendocrinology
The study of the interaction and communication between the neurological and endocrine systems is known as neuroendocrinology. The brain and endocrine systems typically collaborate to control the physiological forms of the human body, a process called as neuroendocrine integration. Since it was discovered that the brain, particularly the hypothalamus, controls pituitary hormone production, neuroendocrinology has grown to examine a variety of relationships between the endocrine and neurological systems. The neuroendocrine framework is the mechanism by which the hypothalamus regulates production, digestion, eating and drinking habits, energy utilisation, osmolality, and blood weight in order to maintain homeostasis.
1. Types of cancer and neuroendocrine systems
2. Behavioural Neuroendocrinology
3. Idiopathic Short Stature
4. Neuroendocrine Pancreatic cancer
5. Hormone Therapy for Hyposecretion
Track 17: Endocrine Oncology
The branch of medicine known as endocrine oncology deals with thyroid hormone-induced tumours, also referred to as endocrine neoplasia. Endocrine neoplasia comes in two different varieties, both of which are genetic disorders that can be handed down from parent to child. Both types—the first known as warmers disorder and the second as pheochromocytoma or simple condition—lead to medullary thyroid cancer.
1. Adrenal gland tumors
2. Multiple endocrine neoplasias 1 (MEN1)
3. Multiple endocrine neoplasias 2 (MEN 2)
4. Parathyroid gland tumors
5. Pituitary gland tumors
6. Thyroid cancer
7. Pancreatic cancer
Track 18: Endocrinology and Nephrology
The kidneys can be affected by systemic conditions like immune system disorders and diabetes mellitus, and clutters can pave the way for severe or recurrent kidney infections. It has been estimated that 10% to 15% of the general population globally suffers from chronic kidney infection, and treating renal illness is challenging. Heavy metals and other endocrine-disrupting compounds may aid in the improvement and development of chronic renal disease. Due to common pathophysiologic connections, nephrology and endocrinology have a well-known and significant overlap. Even though the kidney is crucial for maintaining body homeostasis, which includes fluid and electrolyte balance as well as administrative control of blood pressure, it's important to realise that it performs many endocrine functions in addition to serving as an important receptor for erythropoietin and other renin-angiotensin-aldosterone system hormones.
1. Diabetes Mellitus and Autoimmune Disease
2. Autoimmune Disease
3. Chronic Kidney Disease
4. Endocrine Disrupting Chemicals
5. Diabetic Nephropathy.
Track 19: Endocrinology: Molecular and Cellular
The field of cellular and molecular endocrinology studies the atomic structure and cell biology of hormones and the endocrine glands that produce them. Calcium's significance in atherogenesis, thyroid problems, muscle metabolism, and bone metabolism are the main topics of cellular and molecular endocrinology study. The uses of DNA technology in several fields will be covered in this session. This session's major goal is to discuss the latest recent methods and findings in cellular and molecular endocrinology and use them to address endocrine problems.
1. Recombinant DNA technology
2. Pathophysiology of diabetes
3. Autoimmune Disease: T1D
4. Insulin Resistance: T2D
Track 20: Exercise, Nutrition, and Metabolism
Vitamins and other nutrients play an inescapable part in the regulation of diabetes since nutrition and blood glucose regulation in our bodies are closely linked. Malnutrition exacerbates diabetes. Statistics show that only 15–38% of people are undernourished. For managing and preventing diabetes, dietary considerations and regular exercise are essential. Diabetes also affects the body's metabolism, which should normally be in good working order. An abnormal metabolism affects the patient's entire body. Faulty metabolism contributes to issues with insulin synthesis and receptors, which makes diabetes a chronic condition. Diabetes' nutritional and metabolic elements will be covered in this lecture.
1. Early childhood nutrition
2. Dietary modification for Diabetes
3. Influence of traditional therapy on diabetes
4. Metabolic disorders and drug metabolism
Track 21: Advancements in Diabetes and Endocrinology
To enhance the quality of life for persons with diabetes and other endocrinology illnesses, the Different Diabetes and Endocrinology Center was founded. For diabetes patients, complications and discomfort add to the overwhelming expectation and care. for patients with diverse endocrinology messes, counting knobs inside the endocrine system. Untapped innovations have been created to protect everyone from metabolic disorders.
1. Informatics in the Service of Medicine
2. Bariatric
3. Glucometer
4. Telemedicine Software and other Technologies
5. Treating Obesity and Preventing Related Diabetes
Track 22: Global Diabetes Market
Due to increased innovation and modernization of therapeutic treatments, the diabetes market has undergone a significant transformation during the past 20 years. Medication developers have found it to be a lucrative market because the condition is so widespread and patient numbers are anticipated to rise in the near future. As a result, according to Global Data, a famous data and analytics company, the size of the global market, as measured by pharmaceutical sales, has grown sixfold since 2000. The global market for diabetes monitoring devices is anticipated to increase at a compound annual growth rate (CAGR) of 6.5 percent, from $19.7 billion in 2020 to $27.0 billion in 2025.
1. Diabetes Monitoring Devices Global Market
2. Global Market Trend Analysis
3. Trends in Regulatory and Economic Policy affecting the market.
Global Market Analysis:
Endocrinology Market is expected to reach $52.98 billion in 2021 to $58.37 billion in 2022 at a CAGR of 4.6 %. Endocrinology is a field of medicine that deals with the medical treatment of Diabetics, Metabolism and Obesity. Region/country wise endocrinology market report is available at Endocrinology 2023.
The market for diabetes care devices is made up of companies (organisations, sole proprietors, and partnerships) that provide diabetes care products and services used to monitor and manage blood glucose levels in diabetic patients.
With a compound annual growth rate (CAGR) of 10.2%, the global diabetes care devices market increased from $52.98 billion in 2021 to $58.37 billion in 2022. At least temporarily, the Russia-Ukraine conflict hampered the possibilities of a COVID-19 pandemic-related global economic rebound. Economic sanctions on several nations, a rise in commodity prices, and disruptions in the supply chain due to the conflict between these two nations have all impacted numerous markets around the world. At a CAGR of 5.8%, the market for diabetes treatment devices is anticipated to reach $73.09 billion in 2026.
The illness profile of the global population is being impacted by busy lifestyles and shifting consumer preferences, particularly for non-communicable diseases like diabetes. The main causes of diabetes are long work hours, a lack of exercise, and bad eating and drinking patterns. For instance, more than 95% of those who have diabetes have type 2 diabetes, according to WHO data from 2021. Nearly 537 million persons (20-79 years old) are living with diabetes, according to IDF data from 2021. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. These elements are anticipated to support market expansion during the anticipated time frame.
This analysis predicts that the global market for digital diabetes management would be worth USD 21.90 billion by 2030. From 2022 to 2030, the market is anticipated to grow at a CAGR of 8.0%. The rising prevalence of diabetes worldwide, the rising number of new product launches, and technological advancements including those in artificial intelligence and predictive analytics are the main drivers of market expansion (AI).
In the global diabetes devices market, insulin delivery devices are the category with the quickest rate of growth, accounting for about 56.9% of the market in 2021. The market has been divided into pens, pumps, syringes, and jet injectors based on insulin delivery devices. In 2021, pens had a bigger market share for diabetes devices. However, because it is predicted to develop at the fastest CAGR during the forecast period, the pump sector is anticipated to earn a significant amount of market share.
Over the past few years, the number of smartphone apps for managing diseases has dramatically increased, significantly boosting the industry. For instance, Abbott and Sanofi established non-exclusive cooperation in September 2019 to combine their respective Freestyle Libre mobile applications and cloud-connected insulin pens, making managing diabetes easier.
The prevalence of obesity is rising, the population is getting older, and people are becoming more aware of the importance of diabetes preventive care, all of which contribute to the market's growth. The industry is also fuelled by the rise in active smart device users and the release of new apps that let patients check their blood sugar levels. These apps help medical personnel leverage cutting-edge technologies, improving patient outcomes.
Market Analysis- Europe:
The European Diabetes Drugs Market is anticipated to grow at a CAGR of over 3% throughout the period of the projection.
In 2021, the Europe Diabetes Care Devices Market was valued at USD 6.93 billion. By the end of 2028, the market is anticipated to generate revenues of about $9.86 billion at a CAGR of 5.3%. Due to the rapid advancement of diabetes technology and growing consumer awareness of these devices, the market for diabetes care devices in Europe is seeing tremendous growth. Despite the quickening pace of technological innovation, the market for diabetes treatment devices in Europe is expanding rapidly. While other government initiatives and awareness-raising activities are also bolstering the expansion of the European market for diabetes care equipment. In addition, the incidence of diabetes among the elderly, poor eating habits, and rising levels of physical inactivity. A growing older population, more public awareness, and large R&D expenditures are all factors that support the market's rise. However, it is predicted that the expansion of the Europe Diabetes Care Devices Market will be constrained throughout the forecast period by low per-person diabetes spending and various repercussions coupled with insulin delivery devices.
During the forecast period, which runs from 2023 to 2033, the Europe DIABETES market is expected to experience significant growth. The rising population in various nations, including the United Kingdom, France, Germany, Sweden, the Netherlands, Italy, and Russia, as well as the region's increasing demand for advanced healthcare services, are both key contributors to the market's expansion. In 2021, the total populations of the United Kingdom, France, Germany, Sweden, the Netherlands, Italy, and Russia were 67326569, 67499343, 83129285, 10415811, 17533405, 59066225, and 143446060, respectively, according to World Bank statistics.
On the other hand, the World Bank estimates that the current health expenditure per person in the European Union will increase to USD 3476.43 (in current US dollars) in 2019, from USD 2636.34 in 2006. This increase in current health spending per person is expected to support the expansion of the Europe DIABETES market. Furthermore, health spending per capita in Germany increased from USD 2344 in the year 2000 to USD 5440 in 2019. Additionally, among all the sources of health spending in 2019, contributions to social health insurance (SHI) had the highest percentage (64.90%), followed by transfers from the government (12.83%), and out-of-pocket spending (OOPS) (12.82%). In addition, throughout the projected period, the rising GDP per capita in the European Union is anticipated to present significant potential prospects for the Europe DIABETES market.
During the predicted period, there will be a more than 15% increase in the number of people with diabetes in the European region.
The IDF estimates that the total cost of diabetes among people in Europe aged 20 to 79 was USD 156 billion in 2017 and will rise to USD 174 billion by 2040. According to these data, diabetes accounts for about 9% of all healthcare spending in Europe.
France and Paris Market Analysis:
One of the largest nations in Europe is France. There is a consistent rise in diabetes in this nation, where there are around 3.2 million cases. The number of people with diabetes is predicted to rise across all age groups as a result of the rising obesity rate, growing public awareness, and the high cost of healthcare in this nation.
Over the forecast period, of 2022–2027, the market for diabetes devices in France is anticipated to grow at a rate of over 7%. The market for diabetes equipment in France is divided into two categories: management devices (such as insulin pumps, syringes, cartridges for reusable pens, disposable pens, and jet injectors) and monitoring devices (Self-monitoring Blood Glucose, Continuous Glucose Monitoring). The report provides the value for the aforementioned segments (in USD million).
Over the predicted period of 2022–2027, the population of people with type 1 diabetes increased in France with a CAGR of more than 3%. The IDF EUR area includes 59 countries, including France. Additionally, 537 million people globally and 61 million people in the Europe Region will have diabetes by 2021; by 2045, this figure will rise to 69 million. According to a poll by the EU Commission, one in ten people in France has diabetes, making France the country with the highest percentage of chronic diabetics. Although the guidelines' aim of 80% compliance with indicated healthcare consultations isn't always realised, diabetes prevalence is considerable in France. To lower the burden of problems and hospitalizations related to diabetes, new strategies that concentrate on patient and physician education and information are required. These techniques should promote proactive therapy modification and diminish therapeutic inertia.
Pharmaceuticals known as diabetic medications were created to stabilise and regulate blood glucose levels in diabetics. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The prevalence of diabetes is the greatest among all chronic conditions covered entirely by France's statutory health insurance (SHI), and in the previous ten years, the number of patients insured has increased by a factor of two. One of the biggest nations in the continent of Europe is France. In recent years, diabetes prevalence had alarmingly increased in France. Diabetes patients need to make several adjustments during the day to keep their blood sugar levels within normal ranges. Examples include taking oral anti-diabetic medicine or consuming more carbohydrates while keeping an eye on their blood sugar levels.
The World Health Organization (WHO) estimates that a million people in France have diabetes. In France, diabetes is becoming more common among individuals of all ages, which can be ascribed to an increase in the number of fat people, bad diets, and sedentary lifestyles. As a result, the market for diabetes medications in France is also being driven by several other factors, including the rising prevalence of diabetes and obesity, expanding awareness of diabetic care, healthcare spending, and technological improvements. All decisions about reimbursement are made at the national level and then applied to all countries in France's integrated healthcare system.
Therefore, it is projected that the studied market will expand in France Country as a result of the aforementioned causes.
